Spain Archives

News and Trends 1 Dec 2016

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals. PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 26 at 1.52.35 PM 1 e1477644606273

News and Trends 28 Oct 2016

Meet Spain’s Gold BIOMEDAList in Celiac Disease

This week we’re heading South back to my hometown, Sevilla! Even well into October, the skies are clear and the sun is shining while we drop by Biomedal, this week’s Biotech. City: Sevilla, Spain Founded: 2000 Employees: 31 Financial data: €2.5M in sales with an impressive 60% growth in the last year Mission: The company has three […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Oct 2016

Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease

Forget about Madrid and Barcelona, the island of Mallorca has one of the hottest Biotechs in Spain: Sanifit is targeting calciphylaxis, an orphan disease that affects the huge dialysis market. Sanifit received the highest financing round in Spain last year (and probably ever) with €36.6M in series C. With this money, the company is advancing its candidate SNF472 in […]

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Aug 2016

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

Not all tumours are detectable, which makes them particularly deadly. Researchers at the University of Barcelona have developed an epigenetic test to find them, the first of its kind to diagnose tumour sources. Cancer starts with a tumour, which grows and eventually sheds cells. These cells lodge in other tissues in the body and grow […]

August 31, 2016 - 3 minutesmins - By Evelyn Warner

entrechem oviedo secondary metabolite engineering

News and Trends 12 Aug 2016

EntreChem is going Back to the Future of Drug Discovery

We leave the Netherlands with a smile after visiting FF Pharma in Utrecht this week. Once again, we depart to another part of Europe and this time we’re heading to the North of Spain. Oviedo, the main capital of the Spanish Asturias region, is our final destination and is also where EntreChem, our Biotech of the […]

August 12, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 4 Aug 2016

Marine Drug goes to Phase III trials to treat Lung Cancer

PharmaMar is starting a new Phase III trial, with patients suffering from small cell lung cancer (SCLC). It’ll test the efficacy of its third candidate obtained from marine organisms (PM1183) as a SCLC treatment. PharmaMar is one of the hot Biotechs in Spain, which just saw its second drug finish Phase III trials with good results (and is […]

August 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 22 Jul 2016

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach. City: Barcelona (Spain) Founded: 2000 Employees: 35 Financial Data: €81.50M Market Cap (Bolsa de […]

July 22, 2016 - 2 minutesmins - By Joachim Eeckhout

cinfa amgen biosimilar biotech neutropenia chemotherapy

News and Trends 5 Jul 2016

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

The Spanish Cinfa Biotech’s race to compete with Amgen’s blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials. Neulasta (pegfilgrastim) is a slightly longer acting version of Amgen’s other blockbuster Neupogen (the template for the first ever US approved biosimilar – from Novartis), the combined sales of which account for over 30% of Amgen’s income. […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 18 Apr 2016

Very promising Results for Resistant Lung Cancer

Ariad has presented updated results of an ongoing phase I/II trial for lung cancer, scoring 100% in one-year overall survival. Ariad Pharmaceuticals is developing small molecules to treat difficult cancers, using computational and structural biology research. It is based in Cambridge (US) and Lausanne (Switzerland). One of the hard-to-treat cancers that Ariad is targeting is […]

April 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

tunicates pharma mar sea squirt alplidin trial cancer multiple myeloma

News and Trends 7 Apr 2016

This Successful Phase III Cancer Drug comes from Sea Squirts

PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma. Based in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Jan 2016

Biotech of the week: Vivia Biotech, the Spanish Pioneer in Personalised Medicine

This week we leave the cold winds of Sweden and head south, to warmer weather and say ¡Hola! to Spain and the location for this week, Madrid. This vibrant city is famous for one of the best football teams in the world, the oldest restaurant in the world (opened in 1725!) and is home to the […]

January 29, 2016 - 2 minutesmins - By Philip Hemme

lunar esa melissa terraforming ecosystem space

News and Trends 30 Nov 2015

Extra-Terrestrial Ecosystems: The European Space Agency MELiSSA Program

Researching how to bring sustainable life support systems from Earth to the moon or Mars is the first move by the European Space Agency in making Space livable on the longer term scale. Around 25 years ago the MELiSSA project was born…with the aim of easing human exploration of the Solar System, whilst also serving […]

November 30, 2015 - 4 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us